Allele Symbol Allele Name Allele ID |
Ednrb+ wild type MGI:2152787 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary |
34 genotypes
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
• under severe hypoxia (10% or 5% O2), heterozygotes maintain a steady (and thus higher) cardiac output relative to wild-type controls where cardiac output is decreased to about half of baseline levels
• heterozygotes exhibit a higher dP/dtmax/Ved value, indicating higher cardiac contractility, at baseline as well as under all hypoxia exposures (15%, 10% or 5% O2) relative to wild-type controls
|
|
• under severe hypoxia, blood is significantly less acidic than in wild-type controls
|
|
• below 15% O2 exposure, heterozygotes show only a mild (smaller) increase in blood lactate levels (1.8 +/- 0.75 mmol/L at 10%; 2.28 0.38 mmol/L at 5%) relative to wild-type controls (4.01 +/- 1.05 mmol/L at 10%; 4.92 +/- 0.33 mmol/L at 5%)
• at 5% O2 exposure, heterozygous blood lactate levels are less than half of those in wild-type controls
• however, no significant differences are noted at room air or 15% O2
|
|
• heterozygotes display a significantly lower partial CO2 pressure at room air (21% O2), but not under 15%, 10% or 5% hypoxia, relative to wild-type controls
|
|
• under 5% O2 exposure, heterozygotes show a significant decrease in the relative hypoxic area (%) in brain, heart, and kidney tissue relative to wild-type controls, as shown by pimonidazole staining; this difference is more significant in heart tissue
• however, no significant differences are seen in the intestine or liver
|
|
• in response to severe hypoxia (10% or 5% O2), heterozygotes show no significant change in cardiac output, unlike wild-type controls where cardiac output is reduced to about half of baseline levels
• however, no significant differences are observed at baseline or under mild hypoxia (21% or 15% O2) relative to wild-type controls
|
|
• heterozygotes exhibit a higher dP/dtmax/Ved (maximum rate of pressure change per ventricular end-diastolic volume) at baseline as well as under all subsequent hypoxia exposures (15%, 10% or 5% O2) relative to wild-type controls
|
|
• under severe hypoxia (10% or 5% O2), heterozygotes maintain a steady (and thus higher) cardiac output relative to wild-type controls where cardiac output is decreased to about half of baseline levels
• heterozygotes exhibit a higher dP/dtmax/Ved value, indicating higher cardiac contractility, at baseline as well as under all hypoxia exposures (15%, 10% or 5% O2) relative to wild-type controls
|
|
• in response to 30 min of severe hypoxia (5% O2), all heterozygotes show tolerance to hypoxia-induced hypotension (defined as MAP <40 mmHg) displaying an average MAP 60.5 +/- 53 mmHg, whereas none of wild-type controls are able to maintain MAP >40 mmHg for the entire 30-min period
|
|
• heterozygotes exhibit a higher dP/dtmax/Ved (maximum rate of pressure change per ventricular end-diastolic volume) at baseline as well as under all subsequent hypoxia exposures (15%, 10% or 5% O2) relative to wild-type controls
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• inflammatory response to topical application of arachidonic acid is reduced by 37 or 51%
• pruritic response is normal
|
• algesic response to phenylbenzoquinone is reduced by 80%
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• rugae morphology is disorganized and fragmented in cleft palate, whereas wild-type palates exhibit orderly array of 7-9 rugae
|
• compound mutants display 35% incidence of cleft secondary palate
|
• rugae morphology is disorganized and fragmented in cleft palate, whereas wild-type palates exhibit orderly array of 7-9 rugae
|
• compound mutants display 35% incidence of cleft secondary palate
|
• rugae morphology is disorganized and fragmented in cleft palate, whereas wild-type palates exhibit orderly array of 7-9 rugae
|
• compound mutants display 35% incidence of cleft secondary palate
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• authors state that mice exhibit the same gross morphological defects as observed in Phr1tm1.1Adia homozygotes
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• mice die between E16.5 and E18.5
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• mice die mid-gestation
|
• at E10.5, yolk sacs lack mature blood vessels unlike in wild-type mice
|
• at E10.5
|
• at E10.5
|
• at E10.5, yolk sacs lack mature blood vessels unlike in wild-type mice
|
• randomized
|
• at E10.5
|
• at E10.5
|
• at E10.5
|
• at E10.5
|
• at E10.5
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• mice die by E7.5
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• mice die of respiratory distress at birth
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• life span after tumor development is shorter than in single Tg(Mt1-RET)304Ina hemizygotes
|
• lung metastasis after tumor development is significantly higher than in Tg(Mt1-RET)304Ina hemizygotes
|
• melanomagenesis proceeds without a pre-existing benign lesion, indicating de novo melanoma development
• location and shape of tumors is similar to those in single Tg(Mt1-RET)304Ina hemizygotes
• 68.8% of tumors less than 500 mm3 in size are malignant and the rest (31.2%) are premalignant
• 80.8% tumors from mutants are malignant and the rest are premalignant
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 03/18/2025 MGI 6.24 |
![]() |
|